Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06473584

Study of the Prevalence of Diabetes and Pre-diabetes in Réunion Island

In view of the new priority given to diabetes in Réunion and the implementation of an ambitious plan to combat the disease at regional level, which includes the identification and management of pre-diabetes, the need for up-to-date data on the extent of these 2 diseases (diabetes and pre-diabetes) has become essential.

These two diseases have known risk factors: age, overweight, obesity, high waist circumference, family history, hypertension, eating habits and physical activity, all of which form part of a risk score for developing diabetes: the Findrisk recommended by the Haute Autorité de Santé for identifying people at risk of diabetes. Given the specific population characteristics of Réunion compared with Finland, where this score has been validated, it would seem important to be able to measure these risk indicators in the population as a function of carbohydrate status in order to check that the proposed thresholds are appropriate for the population of Réunion.

Finally, cardiovascular risk has been described as early as the pre-diabetes stage. Given the young age of onset of diabetes in Réunion and the high proportion of diagnoses of diabetes made following the occurrence of a cardiovascular complication, the study of the prognosis of carbohydrate status on the occurrence of complications using the social security information system will be offered on a voluntary basis to study subjects (via a probabilistic social security link).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU La Réunion

Saint-Denis, Reunion

Location status: Recruiting

Location contact

Catherine MARIMOUTOU, MD

CONTACT

[email protected]

262+ 262 90 50 27

Catherine MARIMOUTOU, MD

PRINCIPAL_INVESTIGATOR

Laetitia BERLY, PhD

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have lived in Réunion island for at least one year
  • Be aged between 18 and 75
  • Affiliated to or benefiting from a social security scheme
  • Free, informed and signed consent

Exclusion criteria

  • No main residence on the island or fixed address for at least one year on the island
  • Participation in experimental research
  • Pregnant women
  • Adults under guardianship or legal protection
  • Not understanding French

Treatment and study plan

Diabetes detection

Diagnostic Test

Fasting glycemia on blood sample

Primary outcomes

  1. Estimating the prevalence of glycaemic abnormalities (diabetes and pre-diabetes) in Réunion

    Time frame: Day 1

    Measurement of fasting blood glucose and blood glucose 2 hours after ingesting 75g of glucose (HGPO test) according to Haute Autorite de Sante (HAS) recommendations used in France for diagnosing diabetes and pre-diabetes in people with unknown diabetes

Study contacts

Contact information is provided by the study sponsor or research team.

Catherine MARIMOUTOU, MD, PhD

CONTACT

[email protected]

+262 (0)262 90 50 50

Florence LEFEBVRE D'HELLENCOURT

CONTACT

[email protected]

+262 262 75 34 71

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de la Réunion

Other

Collaborators

  • Agence Régionale de Santé de La Réunion

Registry information

Acronym: PREVADIABRUN

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jun 25, 2024
Registry last updated
Jul 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.